Michael Goldberg joined MDV in 2005 and leads life science investments in the areas of molecular diagnostics, personalized medicine and wireless healthcare with particular interest in oncology, cardiology, immunology and neuroscience. Prior to joining MDV Michael was Managing Director of Jasper Capital and Co-chair of the California Research and Cures Coalition ($3 billion Prop 71 California Stem Cell Research and Cures Initiative). He has also held senior management and operations roles including serving as Chairman and CEO of OnCare, an oncology services company he founded in 1995. Previously, Michael was Founder and Chief Executive Officer of Axion Inc., a cancer-focused healthcare service company he started in 1987 and sold to Bristol-Myers Squibb in 1996. Michael serves as a board member of the California Institute for Regenerative Medicine and of the Western Association of Venture Capitalists. He is also on the advisory councils of the Caltech Division of Biology, the Harvard Center for Genetics and Genomics, the Stanford Neuroscience Institute, and the Berkeley Center for Law and Technology. Michael is also an advisor to the UCSF Center for Translational and Policy Research on Personalized Medicine. He is a member of the Personalized Medicine Coalition and an honorary trustee of the National Childhood Cancer Foundation. Michael received a B.A. from Brandeis University and an M.B.A. from Stanford Graduate School of Business.